Emmy Boerrigter

11PUBLICATIONS
25CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Toxicology (incl. clinical toxicology)Predictive and prognostic markersPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Nov 23, 2025
Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer.

Catharina J P Op 't Hoog, Niven Mehra, Anouk van Kleef

|Dec 17, 2024
Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis.

Catharina J P Op 't Hoog, Sabien J E Bosman, Emmy Boerrigter

|Jun 17, 2024
In depth: The drug interaction between trimethoprim-sulfamethoxazole and folic acid/folinic acid.

Emmy Boerrigter, Elise Joëlle Smolders

|Feb 28, 2024
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.

Nicolette M Fonseca, Corinne Maurice-Dror, Cameron Herberts

|Jul 17, 2023
Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide.

Eva Podgoršek, Niven Mehra, Inge M van Oort

|Mar 30, 2023
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer.

Sofie H Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi

Pageof 2